Form 4: Assertio Holdings Acquired by Zydus in $23.50 Cash Deal

Director Sigurd Kirk reports the disposal of all equity holdings following the completion of Assertio Holdings' merger with Zydus Worldwide DMCC.

Summary

• Assertio Holdings, Inc. (ASRT) completed its merger with Zydus Worldwide DMCC on June 16, 2026.
• All outstanding shares of common stock were cancelled and converted into the right to receive $23.50 per share in cash.
• Reporting person Sigurd Kirk disposed of 12,017 shares of common stock at the merger price.
• Outstanding stock options with exercise prices below the $23.50 offer price were cancelled and converted into cash payments based on the spread.
• Stock options with exercise prices equal to or greater than the offer price were cancelled without payment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the finalization of a previously announced merger.

Positives

• Shareholders received a cash consideration of $23.50 per share upon the completion of the merger.
• Unvested restricted stock units (RSUs) became fully vested immediately prior to the merger effective time.

Negatives

• Stock options with exercise prices exceeding the $23.50 offer price were cancelled with no payout to the holder.

Risks

• The company has ceased to be an independent publicly traded entity following the merger completion.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Zydus Worldwide DMCC; no further independent forward-looking guidance is provided.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated May 13, 2026.

Industry Context

StockSavvy.ai notes that this acquisition represents a consolidation in the pharmaceutical sector, with Zydus expanding its U.S. footprint through the full buyout of Assertio Holdings.

Comparison to Industry Standards

• The $23.50 cash-out price represents the final valuation for shareholders in this take-private transaction.
• The treatment of unvested RSUs and in-the-money options follows standard change-in-control provisions common in pharmaceutical M&A.

Stakeholder Impact

• Shareholders receive cash proceeds for their equity holdings.
• Employees and management are subject to the integration plans of the parent company, Zydus.

Next Steps

• Delisting of Assertio Holdings common stock from public exchanges.

Key Dates

Keywords

Assertio Holdings, ASRT, Merger, Acquisition, Zydus, Form 4, Insider Transaction